Evidence map›Paper›PMID 35362796›Full record

SynthesisEuropean journal of nuclear medicine and molecular imaging2022

Second primary malignancy risk in thyroid cancer and matched patients with and without radioiodine therapy analysis from the observational health data sciences and informatics.

Seok Kim, Ji-In Bang, Dachung Boo, Borham Kim, In Young Choi, SooJeong Ko, Ie Ryung Yoo, Kwangsoo Kim, Junmo Kim, YoungHwan Joo and 9 more

Abstract readMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in European journal of nuclear medicine and molecular imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 3 pooled it
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 3 syntheses or guidelines pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 7 institutions in 1 country.

Seok Kim *Office of eHealth Research and Business, Seoul National University Bundang Hospital, 173rd Street, Gumi-ro, Seongnam-si 436-707, Republic of Korea.
Ji-In Bang *Department of Nuclear Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea.
Dachung BooOffice of eHealth Research and Business, Seoul National University Bundang Hospital, 173rd Street, Gumi-ro, Seongnam-si 436-707, Republic of Korea.
Borham KimOffice of eHealth Research and Business, Seoul National University Bundang Hospital, 173rd Street, Gumi-ro, Seongnam-si 436-707, Republic of Korea.
In Young ChoiDepartment of Medical Informatics, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
SooJeong KoDepartment of Medical Informatics, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Ie Ryung YooDivision of Nuclear Medicine, Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Kwangsoo KimTransdisciplinary Department of Medicine & Advanced Technology, Seoul National University Hospital, Seoul, Republic of Korea.
Junmo KimInterdisciplinary Program in Bioengineering, Seoul National University, Seoul, Republic of Korea.
YoungHwan JooBiomedical Research Institute, Seoul National University Hospital, Seoul, South Korea.
Hyun Gee RyooDepartment of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
Jin Chul PaengDepartment of Nuclear Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
Jung Mi ParkDepartment of Nuclear Medicine, Soonchunhyang University Bucheon Hospital, Gyeonggido, Republic of Korea.
Woncheol JangDepartment of Statistics, Seoul National University, Seoul, South Korea.
Byungwon KimDepartment of Statistics, Kyungpook National University, Daegu, South Korea.
Yangha ChungDepartment of Statistics, Seoul National University, Seoul, South Korea.
Dongyoon YangDepartment of Statistics, Seoul National University, Seoul, South Korea.
Sooyoung YooOffice of eHealth Research and Business, Seoul National University Bundang Hospital, 173rd Street, Gumi-ro, Seongnam-si 436-707, Republic of Korea. yoosoo0@snubh.org.
Ho-Young LeeDepartment of Nuclear Medicine, Office of eHealth Research and Business, Seoul National University Bundang Hospital, 166, Gumi-ro, Seongnam-si 436-707, Republic of Korea. debobkr@snubh.org.ORCID 0000-0001-6518-0602
Seoul National University · KRSeoul National University Bundang Hospital · KRCatholic University of Korea · KRSeoul National University Hospital · KRCHA University Bundang Medical Center · KRSoonchunhyang University · KRThe Catholic University of Korea Seoul St. Mary's Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeRisk of second primary malignancy (SPM) after radioiodine (RAI) therapy has been continuously debated. The aim of this study is to identify the risk of SPM in thyroid cancer (TC) patients with RAI compared with TC patients without RAI from matched cohort.

methodsRetrospective propensity-matched cohorts were constructed across 4 hospitals in South Korea via the Observational Health Data Science and Informatics (OHDSI), and electrical health records were converted to data of common data model. TC patients who received RAI therapy constituted the target group, whereas TC patients without RAI therapy constituted the comparative group with 1:1 propensity score matching. Hazard ratio (HR) by Cox proportional hazard model was used to estimate the risk of SPM, and meta-analysis was performed to pool the HRs.

resultsAmong a total of 24,318 patients, 5,374 patients from each group were analyzed (mean age 48.9 and 49.2, women 79.4% and 79.5% for target and comparative group, respectively). All hazard ratios of SPM in TC patients with RAI therapy were ≤ 1 based on 95% confidence interval(CI) from full or subgroup analyses according to thyroid cancer stage, time-at-risk period, SPM subtype (hematologic or non-hematologic), and initial age (< 30 years or ≥ 30 years). The HR within the target group was not significantly higher (< 1) in patients who received over 3.7 GBq of I-131 compared with patients who received less than 3.7 GBq of I-131 based on 95% CI.

conclusionThere was no significant difference of the SPM risk between TC patients treated with I-131 and propensity-matched TC patients without I-131 therapy.

Indexed as

Neoplasms, Second PrimaryThyroid NeoplasmsAdultData ScienceFemaleHumansInformaticsIodine RadioisotopesMiddle AgedRetrospective StudiesIodine-131Iodine RadioisotopesCommon data modelIodine-131Neoplasm, Second primaryObservational studyRiskThyroid cancer

Identifiers

PMID35362796
OpenAlexW4221067549

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.